Monoclonal antibodies that deplete progranulin levels reduced cancer growth of hepatocellular carcinomas in mice, in part by reducing tumor microvascular density [31] by decreasing progranulin mediated VEGF expression. The gene discussed is GRN; the disease is neoplasm.